RxDoctor Payments Data

Larissa Kruger Gomes, MD

Nephrology · East Providence, RINPI 1275914509

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $3,051 of the $4,215 with a category attached, or 72.4%. Alnylam Pharmaceuticals Inc. accounts for 60.6% of it on its own, with 5 other manufacturers making up the rest.

$4,215in general payments, 2019–2025

Across 33 payments — averaging $127.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alnylam Pharmaceuticals Inc.$3K
  • AstraZeneca$1K
  • Amgen$202
  • Akebia Therapeutics Inc$173
  • Calliditas Therapeutics US Inc.$31
  • Travere Therapeutics, Inc.$26
$2,282,690in research payments, 2019–2025

Across 49 payments — averaging $46,586 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$887K
  • AstraZeneca$690K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$260K
  • Boehringer Ingelheim International GmbH$238K
  • Vertex$170K
  • Alnylam Pharmaceuticals Inc.$27K
  • plus $10K from 1 others

What the payments were for

  • Travel & lodging$3,05172%
  • Food & beverage$1,14627%
  • Education$170%

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,215 in reported general payments places this provider in the 75th percentile of 45 nephrology providers in Rhode Island.

See all nephrology providers in Rhode Island

Medicare billing

Part B allowed, 2024
$125,254
Medicare patients
326
Services billed
1,326

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin86$99,482
FarxigaDapagliflozin Propanediol35$31,006
Clonidine12$2,873
Losartan Potassium110$1,526
Torsemide65$1,387
Bumetanide55$1,261
Cinacalcet Hcl17$1,042
Amlodipine Besylate126$899
Lisinopril114$897
Olmesartan Medoxomil14$639
Calcium Acetate13$599
Calcitriol20$574
Amiloride Hcl16$450
Spironolactone44$435
Metolazone18$381

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$1,228$31,00635 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 45 nephrology providers in Rhode Island.

Other nephrology in East Providence

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →